CRISPR THERAPTC (NASDAQ:CRSP) had their “market perform” rating reissued by Equities research analysts at Oppenheimer Holdings, Inc. in a note issued to investors on Tuesday.
A number of other brokerages have also recently commented on CRSP. Chardan Capital assumed coverage on CRISPR THERAPTC in a research note on Monday, March 27th. They set a “buy” rating and a $23.50 price objective for the company. Cann assumed coverage on CRISPR THERAPTC in a research note on Monday. They set a “market perform” rating for the company. Finally, SunTrust Banks, Inc. assumed coverage on CRISPR THERAPTC in a research note on Thursday, July 13th. They set a “hold” rating and a $16.00 price objective for the company. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $21.92.
Shares of CRISPR THERAPTC (NASDAQ:CRSP) opened at 16.89 on Tuesday. CRISPR THERAPTC has a one year low of $11.63 and a one year high of $25.00. The stock’s market capitalization is $675.55 million. The stock’s 50 day moving average price is $15.61 and its 200 day moving average price is $17.93.
CRISPR THERAPTC (NASDAQ:CRSP) last announced its quarterly earnings data on Thursday, May 11th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.06. The company had revenue of $2.70 million for the quarter. On average, analysts forecast that CRISPR THERAPTC will post ($2.46) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://stocknewstimes.com/2017/07/20/crispr-theraptc-crsp-given-market-perform-rating-by-oppenheimer-holdings-inc-analysts.html.
In other CRISPR THERAPTC news, CEO Rodger Novak sold 10,825 shares of the business’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $15.37, for a total value of $166,380.25. Following the completion of the transaction, the chief executive officer now directly owns 1,225,830 shares of the company’s stock, valued at $18,841,007.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Kurt Von Emster sold 81,435 shares of the business’s stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $17.08, for a total value of $1,390,909.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 451,845 shares of company stock valued at $7,454,471. Insiders own 39.98% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. IHT Wealth Management LLC acquired a new position in CRISPR THERAPTC during the first quarter worth about $110,000. Credit Suisse AG acquired a new position in CRISPR THERAPTC during the first quarter worth about $1,742,000. Paulson & CO. Inc. acquired a new position in CRISPR THERAPTC during the first quarter worth about $1,099,000. Monashee Investment Management LLC boosted its position in CRISPR THERAPTC by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock worth $473,000 after buying an additional 15,000 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in CRISPR THERAPTC by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock worth $16,272,000 after buying an additional 3,070 shares during the last quarter. 24.07% of the stock is owned by hedge funds and other institutional investors.
CRISPR THERAPTC Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related companies with MarketBeat.com's FREE daily email newsletter.
